ArticleFrontiers in oncology2026
FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective and background: Meningiomas are the most prevalent type of primary intracranial tumor. It is essential to conduct an extensive follow-up period to assess the effectiveness of any treatment method. In this study, we present a long-term follow-up series (average ~14 years) of surgical treatments for meningiomas and evaluate the aspects related to their recurrence. Methods: This is a retrospective study focusing on surgeries performed on 99 patients with 102 meningiomas. The study reviews the patients' medical records, operative reports, radiologic examinations, and follow-up data. The surgeries aimed to achieve the most complete and safest removal of the meningiomas, considering the patients' medical conditions and comorbidities. Postoperative CT and MRI scans were obtained for all patients during the follow-up period. Results: The group comprised 79 women and 20 men with a median age of 56 years (range 27-87 years). The mean follow-up period was 171 months (120-280 months). Simpson grades zero, I and II resections were obtained in ~83%. Twenty cases presented recurrence during the follow-up period (~20%). In the non-recurrent group of patients (n=82), Simpson grades "zero, " I, and II were obtained in 86.6% of cases. In the recurrent group (n=20), Simpson grades III and IV were obtained in 80% of cases. Meningiomas were WHO grade 1 in 95.1% of cases, 2 in 3.9%, and 3 in ~1%. Eight recurrent cases (40%) were originally giant meningiomas (>5cm). Previously irradiated accounted for 7% of cases. Mortality rate during the follow-up period was 7%. The Karnofsky Performance Status (KPS) score of 100 and 90 was 87%. Conclusions: This retrospective series has shown that the recurrence of meningiomas after surgery depends on the Simpson grade of resection, which is linked to incomplete tumor removal. The principles of meningioma surgery can help achieve a higher grade of resection while preserving patients' quality of life. Long-term follow-up is essential to verify the effectiveness of any treatment method for meningiomas, and proper surgical treatment provides a high rate of cure and control over 10 years. This retrospective series has determined that the recurrence of meningiomas after surgery depends on the Simpson grade of resection. Technical principles can help improve the extent of resection during surgery while maintaining patients' quality of life, thereby lowering the risk of recurrence. Using advanced microsurgical techniques in combination with new technologies is essential to achieving these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.